Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 853 | 187 | 651 |
| Samples | 769 | 161 | 599 |
| Peptides | 603 | 116 | 494 |
Function
LAMC1 · Laminin subunit gamma 1
Laminins, a family of extracellular matrix glycoproteins, are the major noncollagenous constituent of basement membranes. They have been implicated in a wide variety of biological processes including cell adhesion, differentiation, migration, signaling, neurite outgrowth and metastasis. Laminins, composed of 3 non identical chains: laminin alpha, beta and gamma (formerly A, B1, and B2, respectively), have a cruciform structure consisting of 3 short arms, each formed by a different chain, and a long arm composed of all 3 chains. Each laminin chain is a multidomain protein encoded by a distinct gene. Several isoforms of each chain have been described. Different alpha, beta and gamma chain isomers combine to give rise to different heterotrimeric laminin isoforms which are designated by Arabic numerals in the order of their discovery, i.e. alpha1beta1gamma1 heterotrimer is laminin 1. The biological functions of the different chains and trimer molecules are largely unknown, but some of the chains have been shown to differ with respect to their tissue distribution, presumably reflecting diverse functions in vivo. This gene encodes the gamma chain isoform laminin, gamma 1. The gamma 1 chain, formerly thought to be a beta chain, contains structural domains similar to beta chains, however, lacks the short alpha region separating domains I and II. The structural organization of this gene also suggested that it had diverged considerably from the beta chain genes. Embryos of transgenic mice in which both alleles of the gamma 1 chain gene were inactivated by homologous recombination, lacked basement membranes, indicating that laminin, gamma 1 chain is necessary for laminin heterotrimer assembly. It has been inferred by analogy with the strikingly similar 3' UTR sequence in mouse laminin gamma 1 cDNA, that multiple polyadenylation sites are utilized in human to generate the 2 different sized mRNAs (5.5 and 7.5 kb) seen on Northern analysis. [provided by RefSeq, Aug 2011].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000258341 | P11047 | 853 | 603 |
Gene Properties
Recurrent Mutations
All 603 amino-acid changes on canonical ENST00000258341 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LAMC1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LAMC1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Oral Cavity Carcinoma | 6/54 11% | 0/0 0% |
| Acute Monocytic Leukemia | 0/1 0% | 2/25 8% |
| Endometrial Carcinoma | 9/42 21% | 34/612 6% |
| Non-Small Cell Lung Carcinoma | 28/304 9% | 41/1390 3% |
| Melanoma | 9/210 4% | 67/1899 4% |
| Colorectal Carcinoma | 25/143 17% | 77/3239 2% |
| Hodgkins Lymphoma | 3/16 19% | 1/122 1% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 21/810 3% |
| Cervical Carcinoma | 0/35 0% | 12/422 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Gastric Carcinoma | 3/74 4% | 38/1809 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Other Solid Cancers | 2/94 2% | 30/1515 2% |
| Bladder Carcinoma | 1/58 2% | 19/956 2% |
| Ovarian Carcinoma | 5/109 5% | 16/998 2% |
| Neuroendocrine Tumour | 7/154 5% | 6/577 1% |
| Ewings Sarcoma | 4/63 6% | 1/262 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 24/1592 2% |
| Head and Neck Carcinoma | 0/85 0% | 24/1574 2% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Hepatocellular Carcinoma | 2/46 4% | 28/2210 1% |
| Non-Cancerous | 0/104 0% | 12/830 1% |
| Kidney Carcinoma | 3/85 4% | 20/1862 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 9/752 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Breast Carcinoma | 11/144 8% | 24/3264 1% |
| Other Sarcomas | 1/69 1% | 6/699 1% |
| Glioma | 0/52 0% | 19/2127 1% |
| Plasma Cell Myeloma | 3/44 7% | 0/305 0% |
Mutation Distribution
Where LAMC1 is mutated · all tissues, split by cell line vs tissue
How many mutations in LAMC1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 853 mutations in LAMC1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|